biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 5.2

an Open Access Journal by MDPI

Biomaterial Modifications and Improvement of Their Biocompatibility 2.0

Guest Editors:

Prof. Dr. Viviana di Giacomo
Department of Pharmacy, University G. d'Annunzio, Chieti-Pescara, Italy

Prof. Dr. Agata Przekora
Independent Unit of Tissue Engineering and Regenerative Medicine, Medical University of Lublin, 20-093 Lublin, Poland

Deadline for manuscript submissions:
closed (30 November 2023)

Message from the Guest Editors

Biomaterial is a substance that has been engineered to interact with biological systems for a medical purpose. Biomaterials may be natural or synthetic and are used in medical applications to support, enhance, or replace damaged tissue or a biological function. For years, biomaterials have been required to passively take over the function of a damaged tissue in the long term. However, the role that biomaterials play in the clinical treatment of damaged organs and tissues is changing, and biomaterials are currently expected to trigger and harness the self-regenerative potential of the body in situ. To this end, research is currently focused on changes in various aspects of biomaterials to improve their biocompatibility, i.e., the ability to perform with an appropriate host response.

This Special Issue's Editors invite original contributions and review articles that address the modification of biomaterial aiming to enhance their biocompatibility in various fields of application. These include but are not limited to medical implants, healing and regeneration of human tissue, nanoparticles, and drug delivery systems.

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI